ArticleIndian journal of pharmacology2026
Alloimperatorin attenuates lung tumor progression by targeting oxidative stress and nuclear kappa B factor/Nrf2 pathway dysregulation.
Article in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiethylnitrosamine (DEN) is a potent environmental carcinogen commonly found in cigarette smoke and polluted air, which is strongly associated with the initiation and progression of lung cancer through oxidative stress, inflammation, and dysregulated cell signaling. Alloimperatorin, a bioactive furanocoumarin compound isolated from Angelica dahurica, has demonstrated anti-inflammatory, antioxidant, and anticancer potential. The current study was designed to explore the chemoprotective effect of alloimperatorin against DEN-induced lung cancer in rats and explore the underlying signaling pathways. MATERIALS AND
methodsLung carcinogenesis was induced in male Wistar rats via intraperitoneal administration of DEN, and rats received the oral administration of alloimperatorin for 8 weeks. The lung function, body weight, tumor markers, phase I, phase II, polyamine, inflammatory parameters, inflammatory cytokines, and antioxidant enzymes were assessed. Quantitative histopathological analysis and histopathological observation were done in the lung tissue.
resultsAlloimperatorin significantly ameliorated the tumor burden, tumor number, mean tumor size, and improved histological architecture. Alloimperatorin ameliorate the level of tumor markers (5'-nucleotidase, aryl hydrocarbon hydroxylase, adenosine deaminase, lactate dehydrogenase, Hexosamine, Hexose), hematological parameters (total leucocytes, lymphocytes, total white blood cells count, neutrophils, monocytes, red blood cells counts), pro-inflammatory cytokines (tumor necrosis factor-alpha, L-1β, interleukin 4 [IL-4], IL-6, IL-10, IL-18), inflammatory parameters (cyclooxygenase-2, PGE2, vascular endothelial growth factor, nuclear kappa B factor [NF-κB]), apoptosis (Bax, Bcl-2, caspase-3) while restoring antioxidant enzyme (superoxide dismutase, catalase, glutathione (GSH) peroxidase, GSH, malonaldehyde) activities. In addition, it enhanced the level of HO-1 and Nrf2.
conclusionAlloimperatorin ameliorate the lung cancer via alteration of the NF-κB and Nrf2 signalling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.